LTX-315: what do we know about this experimental cancer therapy?
Clinical review pending
LTX-315 is injected directly into tumors to destroy tumor cells and trigger an immune response. Early trials suggest activity, but a clinical benefit remains unestablished. It is not approved.
Whether LTX-315 provides a clinical benefit for people with cancer has not yet been established. Early studies show changes in tumor tissue and signs of an immune response. However, the human studies have no control group against which to compare the results. LTX-315 is investigational and is not approved.
What is LTX-315?
LTX-315, also called Oncopore and ruxotemitide, is an investigational peptide—a chain of nine amino acids. It is injected directly into a tumor to destroy tumor cells and trigger an immune response. Lytix Biopharma is developing it for solid tumors, including melanoma. Clinical trials are investigating LTX-315 both alone and together with immunotherapy.
How does LTX-315 work?
LTX-315 inserts into cell membranes and disrupts their structure. Tumor cells then rupture, releasing tumor antigens and “danger signals.” Tumor antigens are structures through which the immune system can recognize tumor cells. 1
This form of cell death is intended to trigger an immune response and attract cancer-fighting T cells. The hope is that the immune response will also reach tumors that were not injected. An effect beyond the treated tumor is called an “abscopal effect.” Whether LTX-315 provides a clinical benefit through this process remains an open question.
LTX-315 is also being studied alongside immune checkpoint inhibitors, a form of immunotherapy. The rationale is that released tumor antigens may strengthen the immune response. This possible mechanism alone does not establish how effective treatment is in people.
Is LTX-315 FDA-approved?
No. LTX-315 is still undergoing clinical testing and is not approved. Its two development programs are at different stages:
| Program | Developer | Indication | Regulatory development status |
|---|---|---|---|
| LTX-315 | Lytix Biopharma | Resectable high-risk melanoma | According to the company, FDA feedback supports a path to a phase 3 trial whose results could support approval. Such a trial has not yet been completed. |
| VP-315 (licensed LTX-315) | Verrica Pharmaceuticals | Basal cell carcinoma | In 2021, the FDA accepted the Investigational New Drug Application (IND) for this program 2. This allowed a phase 2 clinical trial to begin. It did not constitute marketing approval. |
What does the research show?
Human data so far come from early studies without control groups. In a phase 1 trial involving people with advanced solid tumors, researchers investigated different doses. They reported the following observations: 1
- Tumor necrosis, meaning dead tumor tissue;
- Cancer-fighting T cells entering tumor tissue;
- Shrinkage of injected tumors by at least 30% in some patients;
- Signs of an immune response throughout the body.
However, shrinkage of individual injected tumors does not mean that the treatment as a whole met the usual criteria for an objective response. Such a response was not observed with LTX-315 alone.
Later phase 2 findings and results from studies combining it with other therapies were published mainly in company announcements. Controlled efficacy trials are not yet available. The changes observed in tumor tissue and signs of an immune response therefore do not yet allow a reliable conclusion about clinical benefit.